FDA Raids Cancer Clinic, Confiscates Laetrile
April 26th, 2013 // 2:29 am @ jmpickett
Updated Daily – Read our latest FDA, cGMP Compliance News
FDA shut down a cancer clinic in Tulsa, OK this week, after federal agents appeared at Camelot Cancer Care in the southern part of Tulsa and issued a search warrant.
It appears that FDA was there because the cancer center was using Laetrile which is a drug that has not been approved for cancer treatments.
One couple was at the clinic at the time, and the wife is very ill with cancer and no longer wants chemotherapy or radiation. The husband said that he had paid $13,000 from his savings to pay for a treatment program of 20 days. They had already finished eight days of the treatments. But FDA and the FBI showed up and they told the man and his wife to leave the medications there that they had paid for.
April 29 – Audit Your Lab Like an FDA Auditor – A Roadmap to cGMP Lab Compliance
Camelot Cancer Center is an alternative treatment cancer center that fights the deadly disease with all natural medicines.
The chemical, laetrile is found in the pits of various fruits and nuts. While the chemical is listed on the center’s website, it is not approved by FDA.
During the search, one of the employees was arrested for shoving an officer as he was trying sneak a PC out of the office. The man was put in jail on a complaint of assault/battery on a police officer.
Camelot has not been shut down by FDA at this time, but it needs to make changes in its treatment plans in the future.
- April 29 – Audit Your Lab Like an FDA Auditor – A Roadmap to cGMP Lab Compliance
- April 30 – How to Prepare Yourself for 21 CFR Part 11 Inspections
- May 1 – Avoiding Warning Letter Disasters With a Strong cGMP and GCP Quality Agreement
- May 2 – Avoid the CDRH eCopy Confusion – How to Prepare a Compliant eCopy Submission
- May 7 – FDA Recall Chief Update – How to Design a Bulletproof Recall Strategy
- May 13 – Breaking Regulatory Update for Life Science Firms – UFA Requirements for eCTDs
- May 14 – How to Effectively Source OTC, Generics and APIs from Indian Pharma Manufacturers
- May 15 – FDA Chief Counsel Report – How to Deal With and Avoid Warning Letters
- May 16 – Spend $500K on Compliance or $300 Million on Consent Decree? – Essential cGMP Compliance Tips for Sr. Management
- May 30 – The Essentials of Complaint Handling and Post Market Management – How to Comply With Global Regulatory Requirements
